Pharmacodynamic Studies
Services Project
- Immune cells analysis
- Tumour-infiltrating lymphocyte analysis
- Multi-cytokine analysis
- Receptor occupancy (RO) analysis
Case Studies
Fig. FACS detection of immune cell infiltration in subcutaneous graft tumours.(**P<0.01,*P<0.05)
SMOC provides a comprehensive portfolio of predefifined cytokine panels, offffering flflexible selection aligned with drug mechanisms and experimental objectives. Our assays achieve high sensitivity down to 10 pg/mL, with select ultra-sensitive platforms reaching 274 fg/mL. Detection covers diverse biospecimens—including serum, plasma, tears, aqueous humor, saliva, body cavity lavage flfluids, cell supernatants, and tissue lysates—across mouse, rat, non-human primate, and human for immunology, oncology, neurology, and functional research.
Pharmacokinetic Studies
Services Project
- PK Studies
- LC/MS Detection of Small Molecule and Peptide Drugs
- ELISA-Based Detection of Antibody Drugs
- Abs/ADA Detection
Case Studies
In vitro Pharmacodynamic Evaluation Service provides related cell experimental services such as cell viability testing, ADCC/TDCC assays, mixed lymphocyte reaction (MLR) assays, complement-dependent cytotoxicity (CDC) assays, and antibody-drug conjugate (ADC) bystander assays.
Services Project
- ADCC/TDCC
- MLRStudies
- CDCStudies
- ADCbystander effect detection
Case Studies
The mixed lymphocyte reaction (MLR) is commonly used to determine the degree of compatibility between the major histocompatibility complex (HLA) antigens of a recipient and a donor. It is a system involving the co-culture of primary dendritic cells (DCs) and T cells, and is frequently used to assess DC-mediated T cell activation.
Sample: mDC+CD4+T cells+Compound
Vehicle control: mDC+CD4+T cells+Medium
Medium: Medium
Antibody-based therapies often require the use of the complement-dependent cytolysis (CDC) assay to evaluate their efficacy. The CDC assay assesses the ability of a candidate drug to destroy specific target cells through multiple pathways mediated by the complement system.
The CDC assay typically involves incubating target cells, the antibody under test, and serum (as a source of complement) together at 37°C for 1–24 hours, after which the lysed dead cells or live cells can be examined.
Antibody-dependent cellular cytotoxicity (ADCC) is a key immune mechanism in which effector cells lyse target cells via membrane surface antigens bound by specific antibodies; it also forms the basis for many current antibody therapies.
When the drug in an ADC is released after being internalized and degraded within the target cell, or when it is released into the extracellular space, it induces bystander killing, which is one of the key mechanisms by which ADCs exert their effects.
Ex vivo & In vitro Pharmacodynamic Evaluation Service Platform
